BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 34386839)

  • 1. What's behind
    Rüschoff JH; Ferraro DA; Muehlematter UJ; Laudicella R; Hermanns T; Rodewald AK; Moch H; Eberli D; Burger IA; Rupp NJ
    Eur J Nucl Med Mol Imaging; 2021 Nov; 48(12):4042-4053. PubMed ID: 34386839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and
    Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW
    BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with
    Ferraro DA; Rüschoff JH; Muehlematter UJ; Kranzbühler B; Müller J; Messerli M; Husmann L; Hermanns T; Eberli D; Rupp NJ; Burger IA
    Theranostics; 2020; 10(14):6082-6094. PubMed ID: 32483440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How accurate is
    Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
    Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic accuracy of
    Scheltema MJ; Chang JI; Stricker PD; van Leeuwen PJ; Nguyen QA; Ho B; Delprado W; Lee J; Thompson JE; Cusick T; Spriensma AS; Siriwardana AR; Yuen C; Kooner R; Hruby G; O'Neill G; Emmett L
    BJU Int; 2019 Nov; 124 Suppl 1():42-49. PubMed ID: 31287613
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Klingenberg S; Jochumsen MR; Ulhøi BP; Fredsøe J; Sørensen KD; Borre M; Bouchelouche K
    J Nucl Med; 2021 Feb; 62(2):214-220. PubMed ID: 32444374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical Validation of PSMA Expression Measured by
    Woythal N; Arsenic R; Kempkensteffen C; Miller K; Janssen JC; Huang K; Makowski MR; Brenner W; Prasad V
    J Nucl Med; 2018 Feb; 59(2):238-243. PubMed ID: 28775203
    [No Abstract]   [Full Text] [Related]  

  • 9. Can
    Yin H; Chen M; Qiu X; Qiu L; Gao J; Li D; Fu Y; Huang H; Guo S; Zhang Q; Ai S; Wang F; Guo H
    Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3693-3701. PubMed ID: 33813594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment and prospective validation of an SUV
    Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
    Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
    [No Abstract]   [Full Text] [Related]  

  • 11.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer?
    Demirci E; Kabasakal L; Şahin OE; Akgün E; Gültekin MH; Doğanca T; Tuna MB; Öbek C; Kiliç M; Esen T; Kural AR
    Nucl Med Commun; 2019 Jan; 40(1):86-91. PubMed ID: 30395048
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI.
    Laudicella R; Rüschoff JH; Ferraro DA; Brada MD; Hausmann D; Mebert I; Maurer A; Hermanns T; Eberli D; Rupp NJ; Burger IA
    Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3917-3928. PubMed ID: 35435496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diverse PSMA expression in primary prostate cancer: reason for negative [
    Cytawa W; Kircher S; Kübler H; Werner RA; Weber S; Hartrampf P; Bandurski T; Lass P; Połom W; Matuszewski M; Wester HJ; Lapa C; Rosenwald A; Seitz AK; Buck AK
    Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3938-3949. PubMed ID: 35556160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlations of the
    Karyagar SS; Karyagar S; Guven O
    Hell J Nucl Med; 2020; 23(2):120-124. PubMed ID: 32716402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive evaluation of
    Gao J; Xu Q; Fu Y; He K; Zhang C; Zhang Q; Shi J; Zhao X; Wang F; Guo H
    Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):561-569. PubMed ID: 32623502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standardised uptake values as determined on prostate-specific membrane antigen positron emission tomography/computed tomography is associated with oncological outcomes in patients with prostate cancer.
    Bodar YJL; Veerman H; Meijer D; de Bie K; van Leeuwen PJ; Donswijk ML; van Moorselaar RJA; Hendrikse NH; Boellaard R; Oprea-Lager DE; Vis AN
    BJU Int; 2022 Jun; 129(6):768-776. PubMed ID: 35166426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of preoperative locoregional Ga-68 PSMA-11 PET-CT and mp-MRI results with postoperative histopathology of prostate cancer.
    Yilmaz B; Turkay R; Colakoglu Y; Baytekin HF; Ergul N; Sahin S; Tugcu V; Inci E; Tasci AI; Cermik TF
    Prostate; 2019 Jun; 79(9):1007-1017. PubMed ID: 31012125
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Pepe P; Pepe L; Tamburo M; Marletta G; Savoca F; Pennisi M; Fraggetta F
    In Vivo; 2023; 37(3):1318-1322. PubMed ID: 37103095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.